Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 356

1.
3.

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.

Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E.

Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x.

PMID:
24420962
4.

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.

Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT.

J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008.

PMID:
19896326
5.
6.
7.

A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.

Hoggart B, Ratcliffe S, Ehler E, Simpson KH, Hovorka J, Lejčko J, Taylor L, Lauder H, Serpell M.

J Neurol. 2015 Jan;262(1):27-40. doi: 10.1007/s00415-014-7502-9.

PMID:
25270679
8.
9.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Rog DJ, Nurmikko TJ, Friede T, Young CA.

Neurology. 2005 Sep 27;65(6):812-9.

PMID:
16186518
11.

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT.

J Pain. 2012 May;13(5):438-49. doi: 10.1016/j.jpain.2012.01.003.

PMID:
22483680
12.

Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial.

Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D.

Pain. 2007 Dec 15;133(1-3):210-20.

PMID:
17997224
13.

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.

Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR.

Curr Med Res Opin. 2007 Jan;23(1):17-24.

PMID:
17257464
14.

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.

Koehler J, Feneberg W, Meier M, Pöllmann W.

Int J Neurosci. 2014 Sep;124(9):652-6. doi: 10.3109/00207454.2013.877460.

PMID:
24392812
15.
17.

A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.

Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM.

Hum Psychopharmacol. 2011 Apr;26(3):224-36. doi: 10.1002/hup.1196.

PMID:
21671456
18.

Advances in the management of multiple sclerosis spasticity: recent clinical trials.

Fernández O.

Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616.

PMID:
25278117
19.

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.

Stott CG, White L, Wright S, Wilbraham D, Guy GW.

Eur J Clin Pharmacol. 2013 Apr;69(4):825-34. doi: 10.1007/s00228-012-1393-4.

PMID:
23052407
20.

Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.

Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.

Clin Ther. 2007 Oct;29(10):2179-93. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
18042474

Supplemental Content

Support Center